Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun Vasant Balar, Dean F. Bajorin, Robert Dreicer et al.|The Lancet|2016Cited by 2.2k
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerMatti Annala, Kim N., Gillian Vandekerkhove et al.|Cancer Discovery|2018Cited by 520
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxelK.N. Chi, Howard I. Scher, Thian Kheoh et al.|Annals of Oncology|2015Cited by 170
Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway InhibitionMatti Annala, Alexander W. Wyatt, Sinja Taavitsainen et al.|Clinical Cancer Research|2021Cited by 94
Concurrent germline and somatic pathogenic BAP1 variants in a patient with metastatic bladder cancerMegan E. Tesch, Bernhard J. Eigl|npj Genomic Medicine|2020Cited by 11